Biotech Values

[go seek]

$$$ falling to bottomline from m-enox sales

Expect others have calculated the ongoing profits to MNTA for m-enox sales if m-enox remains the sole generic.

In 3rd quarter 2010
$44M Lovenox profit share to MNTA
$35M 100% payback of development costs

$79M TOTAL from m-enox to MNTA in 3rd quarter

****************************************************

Let's round this down to $75M per quarter.

OK, conservatively... MNTA will 'earn' $250M - $300M per year from m-enoxaparin
******************************************************************************************

MNTA's market cap is currently $716M

Comments / calculations you wish to share?